Stanley J. Szefler, MD, Brenda R. Phillips, MS, Fernando D

Slides:

Advertisements

Similar presentations

Individualized therapy for persistent asthma in young children

Advertisements

Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered- dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder.

Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS

Adherence with montelukast or fluticasone in a long-term clinical trial: Results from the Mild Asthma Montelukast Versus Inhaled Corticosteroid Trial

Treatment of nasal polyposis and chronic rhinosinusitis with fluticasone propionate nasal drops reduces need for sinus surgery Albertien A.C. Aukema,

Jonathan Malka, MD, David T

Diane J. Pincus, MD, Stanley J. Szefler, MD, Lynn M

Risk of an asthma exacerbation after bariatric surgery in adults

Asthma morbidity among inner-city adolescents receiving guidelines-based therapy: Role of predictors in the setting of high adherence Rebecca S. Gruchalla,

Anne M. Fitzpatrick, PhD, MSCR, W. Gerald Teague, MD

Guideline-defining asthma clinical trials of the National Heart, Lung, and Blood Institute's Asthma Clinical Research Network and Childhood Asthma Research.

Theresa W. Guilbert, MD, David T. Mauger, PhD, David B

Differential effects of maintenance long-acting β-agonist and inhaled corticosteroid on asthma control and asthma exacerbations Peter G. Gibson, MBBS(Hons),

Stephen P. Peters, MD, PhD, Eugene R. Bleecker, MD, Susan J

Individualized therapy for persistent asthma in young children

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: The Pediatric Asthma Controller Trial Christine A. Sorkness,

Jan Lötvall, MD, Cezmi A. Akdis, MD, Leonard B

Caregivers report a wide variety of early signs and symptoms of impending asthma exacerbations that are not different between preschool and school-aged.

Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies Stuart W Stoloff,

Serum vitamin D levels and severe asthma exacerbations in the Childhood Asthma Management Program study John M. Brehm, MD, MPH, Brooke Schuemann, BS,

Is 9 more than 2 also in allergic airway inflammation?

Desensitization to Chemotherapeutic Agents

Allergy immunotherapy among Medicaid-enrolled children with allergic rhinitis: Patterns of care, resource use, and costs Cheryl S. Hankin, PhD, Linda.

Childhood Asthma-Predictive Phenotype

Stanley J. Szefler, MD, Richard J. Martin, MD

Relationship of exhaled nitric oxide to clinical and inflammatory markers of persistent asthma in children Robert C. Strunk, MD, Stanley J. Szefler,

The Childhood Asthma Control Test∗: Retrospective determination and clinical validation of a cut point to identify children with very poorly controlled.

Treatment of chronic autoimmune urticaria with omalizumab

Theresa W. Guilbert, MD, David T. Mauger, PhD, David B

Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate-to-severe intermittent wheezing Leonard.

Markers of Differential Response to Inhaled Corticosteroid Treatment Among Children with Mild Persistent Asthma Joe K. Gerald, MD, PhD, Lynn B. Gerald,

Maternal microchimerism protects against the development of asthma

Jewlya Lynn, PhD, Sophie Oppenheimer, MS, MPH, Lorena Zimmer, MA

High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effects William Busse, MD, Sheldon Spector, MD, Karin Rosén,

A review of the current guidelines for allergic rhinitis and asthma

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Do oral corticosteroids reduce the severity of acute lower respiratory tract illnesses in preschool children with recurrent wheezing? Avraham Beigelman,

A cluster-randomized trial shows telephone peer coaching for parents reduces children's asthma morbidity Jane M. Garbutt, MB, ChB, Yan Yan, MD, PhD,

Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS

Claus Bachert, MD, PhD, Cezmi A. Akdis, MD

What is an “eosinophilic phenotype” of asthma?

Aaron Deykin, MD, Stephen C. Lazarus, MD, John V

H. William Kelly, PharmD Journal of Allergy and Clinical Immunology

Autophagy: Nobel Prize 2016 and allergy and asthma research

Development and cross-sectional validation of the Childhood Asthma Control Test Andrew H. Liu, MD, Robert Zeiger, MD, Christine Sorkness, PharmD, Todd.

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Adherence with montelukast or fluticasone in a long-term clinical trial: Results from the Mild Asthma Montelukast Versus Inhaled Corticosteroid Trial

Diagnosis and management of early asthma in preschool-aged children

Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered- dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder.

Mary F. Linehan, PhD, Timothy L. Frank, MD, Michelle L

Asthma control, adiposity, and adipokines among inner-city adolescents

One step forward, 2 steps back: The enigma of preschool wheeze

Asthma morbidity among inner-city adolescents receiving guidelines-based therapy: Role of predictors in the setting of high adherence Rebecca S. Gruchalla,

The Editors' Choice Journal of Allergy and Clinical Immunology

Jessica H. Savage, MD, MHS, Elizabeth C. Matsui, MD, MHS, Robert A

Diane J. Pincus, MD, Stanley J. Szefler, MD, Lynn M

Azithromycin or montelukast as inhaled corticosteroid–sparing agents in moderate-to- severe childhood asthma study Robert C. Strunk, MD, Leonard B. Bacharier,

Macrolide antibiotics and asthma treatment

Budesonide Inhalation Suspension Versus Montelukast in Children Aged 2 to 4 Years with Mild Persistent Asthma Stanley J. Szefler, MD, Lars-Goran Carlsson,

Statistical issues in clinical trials that involve the double-blind, placebo-controlled food challenge Vernon M. Chinchilli, PhD, Laura Fisher, MD, Timothy.

Theresa W. Guilbert, MD, David T. Mauger, PhD, David B

Asthma Control Test: Reliability, validity, and responsiveness in patients not previously followed by asthma specialists Michael Schatz, MD, MS, Christine.

Caroline C. Horner, MD, MSCI, Courtney Dula, MS, Leonard B

Advances in pediatric asthma in 2007

Natural history of cow’s milk allergy

The Editors' Choice Journal of Allergy and Clinical Immunology

Modeling asthma exacerbations through lung function in children

Development and validation of the Composite Asthma Severity Index—an outcome measure for use in children and adolescents Jeremy J. Wildfire, MS, Peter.

Presentation transcript:

Characterization of within-subject responses to fluticasone and montelukast in childhood asthma Stanley J. Szefler, MD, Brenda R. Phillips, MS, Fernando D. Martinez, MD, Vernon M. Chinchilli, PhD, Robert F. Lemanske, MD, Robert C. Strunk, MD, Robert S. Zeiger, MD, PhD, Gary Larsen, MD, Joseph D. Spahn, MD, Leonard B. Bacharier, MD, Gordon R. Bloomberg, MD, Theresa W. Guilbert, MD, Gregory Heldt, MD, Wayne J. Morgan, MD, Mark H. Moss, MD, Christine A. Sorkness, PharmD, Lynn M. Taussig, MD Journal of Allergy and Clinical Immunology Volume 115, Issue 2, Pages 233-242 (February 2005) DOI: 10.1016/j.jaci.2004.11.014 Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Fig 1 Study cohort and enrollment disposition for each period and sequence. Treatment failure was defined as an asthma exacerbation that required systemic steroid therapy. A weighted χ2 test is applied to test for differences in treatment failure rates for the 2 medications, weighting by the sample size in each period. Not all children who completed visit 6 had complete data for FEV1. Journal of Allergy and Clinical Immunology 2005 115, 233-242DOI: (10.1016/j.jaci.2004.11.014) Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Fig 2 A, Variability of response and differential response to fluticasone and montelukast, as measured by change in FEV1. Four regions show categories of response, defining a favorable response as 7.5% or greater. FP, Fluticasone propionate; Mt, montelukast. The line of identity is designated, with patients favoring montelukast falling above the line, and those favoring fluticasone falling below the line. The concordance correlation with 95% CIs is displayed. B, Difference in FEV1 response between fluticasone propionate and montelukast for individual participants. Each line designates a single participant. Journal of Allergy and Clinical Immunology 2005 115, 233-242DOI: (10.1016/j.jaci.2004.11.014) Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Fig 3 Univariable odds ratios for the odds of response with selected markers compared with the odds of response without the marker, where response for improvement in FEV1 of 7.5% or greater is shown separately for each medication. Horizontal lines represent 95% CIs. The odds ratios are shown on a logarithmic scale. Journal of Allergy and Clinical Immunology 2005 115, 233-242DOI: (10.1016/j.jaci.2004.11.014) Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions